Background Progress in characterising the humoral immune response to Severe Acute
Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist …

Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …

The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …

The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic continues,
with devasting consequences for human lives and the global economy,. The discovery and …

The SARS-CoV-2 pandemic has resulted in millions of infections, yet the role of host
immune responses in early COVID-19 pathogenesis remains unclear. By investigating 17 …

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) develop neutralizing antibodies that target the viral spike protein. In this study, we …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
stresses the continued need for next-generation vaccines that confer broad protection …

Antibodies are key immune effectors that confer protection against pathogenic threats. The
nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined …

Abstract The outbreak of Coronavirus Disease-2019 (COVID-19) caused by Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has threatened health worldwide. As of …